Glutathione Injectable and Inhalation Products Recalled Due to Sterility Assurance Failure
Pharmacy Innovations is recalling multiple glutathione products due to insanitary facility conditions that compromise sterility assurance. The recall affects inhalation and injectable formulations distributed nationwide.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall for sterility failure in injectable and inhalation products due to insanitary facility conditions. No reported illnesses or hospitalizations; the hazard is a risk-of-harm scenario where preventative action was taken before injury occurred.
Plain-English summary
Pharmacy Innovations is recalling glutathione L-reduced products in multiple formulations, including inhalation nebulizers (100 mg/mL and 200 mg/mL) and injectable vials (220 mg/mL, 500 mg/mL single and double vials) due to lack of assurance of sterility.
An FDA inspection of the manufacturing facility in Erie, Pennsylvania revealed insanitary conditions that compromise the sterility of these products. Injectable and inhalation medications must be sterile to prevent serious infections and other complications.
These products have been distributed nationwide. Consumers using these products should discontinue use and consult their healthcare provider. Healthcare providers should identify and contact patients who may have received affected batches.
The recalled product
- Product
- GLUTATHIONE L REDUCED 100MG/ML (2ML NEBVL) INHALATION; GLUTATHIONE L REDUCED 200MG/ML (1ML NEBVL) INHALATION; GLUTATHIONE L REDUCED 220MG/ML (30ML VIAL) INJECTABLE; GLUTATHIONE L REDUCED 500MG/ML (1ML VIAL) INJECTABLE; GLUTATHIONE L REDUCED 500MG/ML (2ML VIAL) INJECTABLE; GLUTATH
- Manufacturer
- Pharmacy Innovations
- Category
- Drug — Injectable / Inhalation
- Hazard
- sterility-failure
- contamination
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- t20221129@68 t20221025@32 t20221025@33 t20221114@27 t20221021@40 t20221116@36
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27